Yan Leyfman

Yan Leyfman: CRISPR-Cas9 to knock out CISH in tumor-infiltrating lymphocytes for patients with metastatic GI cancers

Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Emil Lou, et al. on LinkedIn:

“Researchers evaluated a first-in-human approach using CRISPR-Cas9 to knock out CISH, an intracellular immune checkpoint, in tumor-infiltrating lymphocytes (TILs) for patients with metastatic GI cancers.

  • Safe administration confirmed.
  • Early signs of anti-tumor activity.
  • 1 patient with MSI-high colorectal cancer had a complete, ongoing response >21 months.

This study highlights a novel strategy to overcome resistance to current immunotherapies.”

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial.

Journal: Elsevier

Authors: Emil Lou, et al.

Yan Leyfman: CRISPR-Cas9 to knock out CISH in tumor-infiltrating lymphocytes for patients with metastatic GI cancers

More posts featuring Yan Leyfman.

cancer CISH colorectal cancer CRISPR-Cas9 Elsevier Emil Lou fight against cancer Global fight against cancer intracellular immune checkpoint Lymphocytes MedNews Week metastatic GI cancers OncoDaily Oncology Yan Leyfman